KDC-MN-228 – Kodiac biolabs

Plain-language summaryIntrigue 62 / 100

Moclobemide (Aurorix) was a major step forward in MAOI design: it blocks MAO-A reversibly rather than permanently, which means dietary tyramine can simply outcompete the drug at the enzyme rather than triggering a crisis. That eliminates the dreaded cheese-effect that has held the older MAOIs back for sixty years. Roche brought it to market in Europe in 1989 and in Canada in 1992, but it never received FDA approval in the US, partly because the company’s Phase 3 trials were not designed to American regulatory standards. Efficacy in depression and social anxiety is solid in European data, comparable to SSRIs. Without the FDA stamp it remains underused in North American practice, which is unfortunate because it is genuinely a more elegant drug than its first-generation predecessors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

42/100

Canonical RIMA reference probe with real MAO-A selectivity utility; clinical edge never materialized

Look, moclobemide had a real idea. Irreversible MAOIs work, but the tyramine interaction is a legitimate safety ceiling that limits who you can put on them. Roche’s morpholine benzamide solved that by binding MAO-A reversibly — tyramine from a meal can simply outcompete it, so the cheese reaction risk collapses. That was a clean piece of pharmacology, and it earned the drug approvals across Europe and Canada through the early nineties. Here’s the thing though: the tyramine story was supposed to be the commercial unlock and it wasnt. Head-to-head against TCAs, moclobemide comes out modestly inferior on efficacy endpoints in most published comparisons. It never crossed the FDA finish line. The class it defines — RIMAs — has stayed small and the compound itself has stayed niche.

The mechanism is single-enzyme inhibition. MAO-A selectivity is roughly 100:1 over MAO-B at low doses, which is clean but not exciting by 2026 standards. We’re scoring mechanism against a landscape that includes dual incretins, mitochondrial peptides, and NMDA channel allosteric modulators. Selective reversible inhibition of one well-mapped enzyme in a saturated antidepressant class just doesn’t move the needle. What you get is predictable: serotonin and norepinephrine accumulation through reduced oxidative deamination, half-life of one to four hours, CYP2C19 clearance, twice-daily dosing. Nothing here is opaque.

Where moclobemide earns its score is bench utility. If your research question involves parsing MAO-A vs MAO-B contributions to a phenotype, moclobemide is the tool. It lets you probe MAO-A selectively and reversibly in a way that neither the irreversible drugs nor the less selective agents allow. Wash-out is fast given the short half-life, which matters for crossover designs. We’d describe it as the selegiline counterpart for MAO-A work — not exciting in isolation, but the right instrument when the question specifically calls for it. The social anxiety disorder literature also gives it a respectable translational footprint; the human signal is genuine even if effect sizes are modest.

The differentiation score reflects its position as the canonical compound in a small class. There’s no meaningful RIMA competitor in active research use, which would normally be a strength, but here the class itself hasn’t grown. Toloxatone exists but never achieved the same uptake. So moclobemide defines its category by default. Honest assessment: if your research program isnt specifically about MAO-A biology or RIMA pharmacology, there are more interesting places to put your attention. For investigators who do need that probe, its actually quite useful. For everyone else, it’s a mature approved drug with a story that largely peaked in the nineties.

Novelty: 22
Mechanism promise: 25
In-category differentiation: 48
Evidence quality: 58
Translational signal: 55
Research bench value: 60

Rationale Moclobemide’s reversibility was genuinely innovative in 1989 but that innovation is now fully absorbed into pharmacology textbooks; efficacy trails TCAs, it never achieved FDA approval, and its primary value in 2026 is as the reference compound for MAO-A selectivity experiments. Bench value keeps the score from bottoming out, but near-zero novelty and a saturated mechanism ceiling keep it well below 50.

Reversible MAO-A inhibitor (RIMA)

A morpholine benzamide reversible inhibitor of MAO-A (RIMA); the first MAOI that does not require dietary tyramine restriction.

Abstract

Moclobemide (4-chloro-N-(2-morpholin-4-ylethyl)benzamide; CAS 71320-77-9; molecular formula C13H17ClN2O2; molecular weight 268.74) is a morpholine benzamide reversible inhibitor of MAO-A (RIMA) developed at Roche and approved in Europe (1989) and Canada (1992) under the trade name Aurorix; never FDA approved for the US market. Distinct from earlier MAOIs by reversible binding: tyramine and other dietary substrates can displace moclobemide from MAO-A, eliminating the requirement for tyramine restriction at typical clinical doses. MAO-A selectivity ratio is approximately 100:1 over MAO-B at low doses. Plasma half-life is 1 to 4 hours; the short half-life dictates twice-daily dosing. Hepatic metabolism via CYP2C19 is the primary clearance pathway. Approved for major depressive disorder and social anxiety disorder. The eliminated tyramine restriction has not produced the expected clinical takeoff: efficacy is modestly inferior to TCAs in head-to-head trials, and the drug remains a niche option. Used as the canonical RIMA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-228Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-228

Moclobemide

Abstract

Read the full monograph